Thili Kulatilake, MD
Family Medicine · Tucson, AZNPI 1396846390
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by GSK at 41.7% of the total. Reporting peaked in 2021 at $718 and has fallen 66.1% since, to $244 in 2025.
Across 32 payments — averaging $76.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$362
- AstraZeneca$245
- Amgen$218
- Cequr Corporation$194
- Amarin Pharma, Inc.$125
- plus $293 from 7 others
Across 53 payments — averaging $34,965 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.6M
- Lexicon Pharmaceuticals, Inc.$212K
- Chiesi USA, Inc.$53K
- Vertex$14K
- Eli Lilly Export S.A. Puerto Rico Branch$11K
What the payments were for
- Food & beverage$2,463100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $1,026 |
| Novo Nordisk | 4 | $362 |
| AstraZeneca | 2 | $245 |
| Amgen(2 entities) | 2 | $218 |
| Cequr Corporation | 1 | $194 |
| Amarin Pharma, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $124 |
| Scilex Pharmaceuticals Inc. | 1 | $48 |
| Pfizer | 2 | $43 |
| Merck | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Insulet Corporation | 1 | $20 |
| Emergent Biosolutions Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$486
- Ozempic$353
- FARXIGA$245
- SHINGRIX$244
- CeQur Simplicity$194
- Vascepa$125
- Otezla$125
- TZIELD$124
- AREXVY$122
How this compares
$2,463 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $22,398 |
| VyvanseLisdexamfetamine Dimesylate | 18 | $7,149 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 94 | $5,136 |
| Lisdexamfetamine Dimesylate | 12 | $2,840 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,644 |
| Rosuvastatin Calcium | 155 | $2,333 |
| SynthroidLevothyroxine Sodium | 23 | $1,800 |
| Morphine Sulfate ErMorphine Sulfate | 57 | $1,736 |
| Gabapentin | 27 | $717 |
| Oxycodone Hcl | 29 | $695 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $685 |
| Losartan Potassium | 78 | $651 |
| Azelastine Hcl | 14 | $610 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $514 |
| Ondansetron OdtOndansetron | 11 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,026 | $22,39819 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $20 | $7,14918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Katherine WilsonTucson$29K
- Kimy CharaniTucson$21K
- Mark GrantTucson$21K
- Christian MoherTucson$13K
- Dean WrightTucson$12K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.